Moving goalposts - Regulatory oversightof antibacterial drugs: The pharma company view

Nature Biotechnology

Volumn 24, Issue 12, 2006, Pages 1515-1519

  Brenner, Randall ^a   Ellis Grosse, Evelyn J ^b  

^a PFIZER INC   (United States)

^b e2g Biopharmaceutical Counseling ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BIOTECHNOLOGY; CLINICAL TRIAL; DRUG APPROVAL; DRUG INDUSTRY; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; HEALTH; HUMAN; INFECTION; INVESTMENT; NOTE; PRIORITY JOURNAL; REGISTRATION;

ANTI-BACTERIAL AGENTS; BIOTECHNOLOGY; CLINICAL TRIALS; DRUG APPROVAL; DRUG INDUSTRY; MICROBIAL SENSITIVITY TESTS; UNITED STATES;

EID: 33845694440     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1206-1515     Document Type: Note

References (30)

1. Powers, J.H. Clin. Microbiol. Infect. 10 (Suppl 4), 23-31 (2004).
2. Weber, J.T. & Courvalin, P. Emerg. Infect. Dis. 11, 791-792 (June 2005).
3. Commission of the European Communities. Communication from the Commission on a Community Strategy Against Antimicrobial Resistance (European Commission, Brussels, Belgium, 2001).
4. World Health Organization. WHO Global Strategy for the Containment of Antimicrobial Resistance (WHO, Geneva, 2001).
5. Nordberg, P., Monnet, D.L. & Cars, O. Antibacterial Resistance. Background Document for the WHO Project: Priority Medicines for Europe and the World - a Public Health Approach to Innovation (WHO, Geneva, 2005). 〈http://mednet3.who.int/prioritymeds/report/index.htm〉
6. Norrby, S.R., Nord, C.E. & Finch, R. Lancet Infect. Dis. 5, 115-119 (2005).
7. Smolinski, M.S., Hamburg, M.A. & Lederberg, J. (eds.). Microbial Threats to Health: Emergence, Detection, and Response (Institute of Medicine, Washington, DC, 2003).
8. Task Force on Antimicrobial Availability. Bad Bugs, No Drugs: As Antibiotic R&D Stagnates, a Public Health Crisis Brews (Infectious Diseases Society of America, Alexandria, Virginia, July 2004). 〈http://www. idsociety.org/pa/IDSA_Paper4_final_web.pdf〉
9. Talbot, G.H. et al. Clin. Infect. Dis. 42, 657-668 (2006).
10. Spellberg, B., Powers, J.H., Brass, E.P., Miller, L.G. & Edwards, J.E., Jr. Clin. Infect. Dis. 38, 1279-1286 (2004).
11. Livermore, D.M. Clin. Microbiol. Infect. 10 (Suppl 4), 1-9 (2004).
12. US Food and Drug Administration. Guidance for Industry: Developing Antimicrobial Drugs - General Considerations for Clinical Trials (FDA, Rockville, Maryland, July 1998). 〈http://www.fda.gov/Cder/guidance/2580dft. pdf〉
13. European Medicines Agency/Committee for Proprietary Medicinal Products. Note for Guidance on Evaluation of Medicinal Products Indicated for Treatment of Bacterial Infections (EMEA/CPMP, London, October 2004). 〈http://www.emea. eu.int/pdfs/human/ewp/055895en.pdf〉
14. Japan Pharmaceutical and Medicine Safety Bureau, Evaluation and Licensing Division. Guidelines for the Clinical Evaluation of Antibacterial Drugs (PMSB/ELD, Tokyo, August 1998).
15. US Food and Drug Administration. Guidelines for the Clinical Evaluation of Anti-Infective Drugs (Systemic Adults and Children) (FDA, Rockville, Maryland, September 1977). 〈http://www.fda.gov/Cder/guidance/old047fn. pdf〉
16. US Food and Drug Administration. FDA Points to Consider - Clinical Development and Labeling of Anti-Infective Drug Products. (FDA, Rockville, Maryland, October 1992). 〈http://www.fda.gov/cder/guidance/ptc.htm〉
17. Blaser, M.J. & Bartlett, J.G. Letter to Acting Commissioner of Food and Drugs Administration. (September 28, 2006). 〈http://www.idsociety.org/ Template.cfm?Section=Home&Template=/ContentManagement/ContentDisplay. cfm&ContentID=17039〉
18. Getz, K.A. A swift predominance of ex-US sites. Applied Clinical Trials Magazine, December 1, 2005. 〈http://www.actmagazine.com/ appliedclinicaltrials/article/articleDetail.jsp?id=261633〉
19. Bakhle, D. Global Clinical Trials in India - Challenges and Opportunities. Business Briefing Pharmatech (Touch Briefings, London, 2003). 〈http://www.touchbriefings.com/pdf/17/pt031_r_4_bakhle.pdf〉
20. International Conference on Harmonization. ICH Harmonized Tripartite Guideline. E5: Ethnic Factors in the Acceptability of Foreign Clinical Data. (ICH, Geneva, February 1998). 〈http://www.ich.org/cache/compo/475-272-1. html#E5〉
21. Temple, R. & Ellenberg, S.S. Ann. Intern. Med. 133, 455-463 (2000).
22. International Conference on Harmonization. ICH Harmonized Tripartite Guideline. E9: Statistical Principles for Clinical Trials (ICH, Geneva, February 1998). 〈http://www.ich.org/cache/compo/475-272-1.html#E9〉
23. International Conference on Harmonization. ICH Harmonized Tripartite Guideline. E10: Choice of Control Group and Related Issues in Clinical Trials. (ICH, Geneva, July 2000). 〈http://www.ich.org/cache/compo/475-272-1. html#E10
24. US Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for Industry. E9 Statistical Principles for Clinical Trials (FDA, Rockville, Maryland, 1998). 〈http://www.fda.gov/cder/guidance/ICH_E9-fnl.pdf〉
25. Federal Food, Drug, and Cosmetic Act, Chapter V - Drugs and Devices Subchapter A, Drugs and Devices, Section 505. 〈http://www.fda.gov/opacom/ laws/fdact/fdtoc.htm〉
26. US Food and Drug Administration. Guidance for Industry. Population Pharmacokinetics (FDA, Rockville, Maryland, February 1999). 〈http://www. fda.gov/cder/guidance/1852fnl.pdf〉
27. US Food and Drug Administration. Antimicrobial Resistance & Drug Development: FDA/IDSA/ISAP Working Group Presentations and Transcripts (FDA, Rockville, Maryland, May, 2004). 〈http://www.fda.gov/cder/drug/ antimicrobial/FDA_IDSA_ISAP_Presentations.htm〉
28. Bradley, J.S., Dudley, M.N. & Drusano, G.L. Pediatr. Infect. Dis. J. 22, 982-992 (2003).
29. Metlay, J.P., Powers, J.H., Dudley, M.N., Christiansen, K. & Finch, R.G. Emerg. Infect. Dis. 12, 183-190 (2006).
30. US Food and Drug Administration. General Principles EMEA-FDA Parallel Scientific Advice Meetings Pilot Program (FDA, Rockville, Maryland, May, 2004). 〈http://www.fda.gov/oia/pilotprogram0904.html〉